What question did this study set out to answer?

The research aims to explore how incretin-based therapy changes the focus from glucose control to reducing cardiovascular and renal risks in diabetes care.

January 10, 2026Diabetes Therapy4 citationsOpen Access

Rewriting Diabetes Therapy: How Incretin Modulation is Transforming Cardiovascular and Renal Outcomes

JMJosé Pablo Miramontes-González ÁRÁlvaro Rodrigo-Alaíz MGMiriam Gabella-Martín

Key Result

Incretin-based therapy, particularly GLP-1 receptor agonists, is endorsed for cardiovascular and renal risk reduction in patients with type 2 diabetes, independent of HbA1c levels.

Key Points

The research aims to explore how incretin-based therapy changes the focus from glucose control to reducing cardiovascular and renal risks in diabetes care.
Review of current guidelines on incretin-based therapies
Analysis of cardiovascular and renal outcomes related to GLP-1 receptor agonists
Evaluation of dual agonists and small-molecule agents pending evidence
Incretin-based therapy shifts focus to cardiorenal risk reduction
GLP-1RA are recommended irrespective of HbA1c levels
Potential for dual agonists and oral agents pending future evidence findings

Structured PICO

Do incretin-based therapies reduce cardiovascular and renal events in patients with T2DM, obesity, CKD, or heart failure?

Population

Patients with type 2 diabetes mellitus (T2DM), obesity without diabetes, chronic kidney disease (CKD), and heart failure (HFpEF/HFrEF) at high cardiovascular or renal risk.

Intervention

Incretin-based therapies including GLP-1 receptor agonists (e.g., liraglutide, semaglutide, dulaglutide), DPP-4 inhibitors, dual GLP-1/GIP agonists (e.g., tirzepatide), and emerging oral small-molecule GLP-1R agonists.

Comparator

Placebo or standard of care (as evaluated in the reviewed cardiovascular and renal outcome trials).

Outcome

Major adverse cardiovascular events (MACE), cardiovascular death, all-cause mortality, heart failure hospitalization, and composite renal outcomes.composite

Incretin-based therapies provide robust cardiorenal protection independent of glycemic control, shifting the treatment paradigm for T2DM, obesity, and heart failure from glucose-centric to risk-reduction strategies.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Incretin-based therapy has shifted care from glucose-centric targets to cardiorenal risk reduction. GLP-1RA are guideline-endorsed for patients with T2DM and high CV/renal risk irrespective of HbA1c; dual agonists and oral small-molecule agents may broaden indications pending definitive outcome evidence.

Ask AI

Helpful

Bookmark

View Full Paper